

CORPORATE FACTSHEET

July 2009

Fast Facts

Headquarters: Netherlands
 Listing: NYSE Euronext, NASDAQ, SWX
 Technology: PER.C6[®], AdVac[®], MAbstract[®], STAR[®], virosomes
 Products: Vaccines and antibody products
 Facilities: Switzerland, Korea, Spain, Sweden, Netherlands
 Partners: Global distribution; broad base of technology licensees
 Market Cap: Approx. €1 bln (29 June 2009)
 Holdings: 6% Galapagos Genomics N.V. (GLPG)
 12% AdImmune Corporation (private)



Mission: Combating infectious diseases

Crucell's mission is to develop, produce and market vaccines and antibodies that prevent or treat infectious diseases.

Crucell at a Glance

Crucell is a fully integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases. We are the largest independent vaccine company in the world.

We develop products that address currently unmet medical needs, particularly in the field of infectious diseases. We have a fully integrated infrastructure for in-house development, production and marketing of vaccines, and we are now leveraging our knowledge in the vaccines field to excel in the antibodies market. Our competitive edge comes from our proprietary technology platforms, like PER.C6[®], which is used to produce high-value biotech products in scalable and cost-efficient ways. This combination of markets we operate in, technological knowledge and quality marketed products, positions us to be a major player in the multi-billion dollar biopharmaceutical arena.

In addition to our own research and development activities, we have strategic partnerships with several leading healthcare companies. Through these agreements, our technologies play a vital role in the development of a vast number of vaccine and antibody products. Our strategic partners include DSM Biologics, Novartis, MedImmune, Merck, sanofi pasteur and Wyeth.

Infectious diseases currently account for a significant number of human casualties throughout the world. The number of infectious outbreaks is increasing for many reasons: higher population density raises exposure to infectious agents; an ageing population which is more susceptible to infection; and the volume of global travel boosts the potential for spreading diseases across borders.

Products

Our vaccine business provides stable and predictable sales and cash flow. We sold more than 100 million vaccine doses in over 80 countries throughout the world, which makes us the largest independent vaccine player. Within vaccines we operate in three main markets: paediatric, travel and endemic, and respiratory.

Quinvaxem[®]	Fully liquid vaccine for protection against five childhood diseases
Hepavax-Gene[®]	Recombinant hepatitis B vaccine
MoRu-Viraten[®]	Vaccine for protection against measles and rubella (all age groups)
Epaxal[®]	Aluminum-free hepatitis A vaccine
Epaxal[®] Junior	Low dosage aluminum-free hepatitis A vaccine (0.25 ml)
Vivotif[®]	Oral typhoid vaccine
Dukoral[®]	Internationally licensed oral vaccine against cholera (and ETEC)
Inflexal[®] V	Virosomal adjuvanted influenza vaccine (all age groups)

Research & Development Pipeline

Our research efforts today are focusing on developing vaccines and antibodies that address unmet medical needs and infectious diseases. Our research efforts are bolstered by our range of technologies, which play a critical role in our development programs.

Development stage	Research/ Preclinical	Phase I	Phase II	Phase III	Marketed	Comment
Marketed products:						
Quinvaxem®						Fully liquid vaccine for protection against five childhood diseases
Hepavax-Gene®						Recombinant hepatitis B vaccine
MoRU-Viraten®						Vaccine for protection against measles and rubella (all age groups)
Epaxal® Junior						Low dosage aluminum-free hepatitis A vaccine (0.25 ml)
Epaxal®						Aluminum-free hepatitis A vaccine
Vivotif®						Oral typhoid vaccine
Dukoral®						Internationally licensed oral vaccine against cholera (and ETEC)
Inflexal® V						Virosomal adjuvanted influenza (all age groups)
Vaccines in development:						
Flavimun®						Yellow Fever vaccine
Influenza seasonal						Epidemic (or seasonal) influenza vaccine ¹
Tuberculosis						Recombinant AdVac®-based tuberculosis vaccine ²
Malaria						Recombinant AdVac®-based malaria vaccine ³
Ebola and Marburg						Recombinant AdVac®-based Ebola and Marburg vaccine ³
HIV						Recombinant HIV vaccine ⁴
Human antibodies in development:						
Rabies antibody combination						Two human antibodies for post-exposure treatment of rabies ⁵
Influenza antibodies H1 and H5						Neutralizing antibody cross reactive against H1N1 and H5N1
Hepatitis C antibodies						Human antibodies against hepatitis C virus
Other:						
Factor V ^{Wc}						Blood coagulation Factor V ^{Wc}

1 Developed by sanofi pasteur using PER.C6®; 2 Partnered with Aeras; 3 Partnered with NIAID/NIH; 4 Partnered with Harvard; 5 Partnered with sanofi pasteur

Technologies

Our strong product portfolio is supported through a range of patented technologies. Our cutting-edge technology platforms enable the discovery, development and production of vaccines, therapeutic proteins and gene therapy products.

PER.C6®

Human designer cell line for the development and large-scale manufacturing of biopharma products

AdVac®

Used in combination with PER.C6®, to develop recombinant vaccines

MAbstract®

Applied for discovery of novel drug targets and identification of human antibodies

STAR®

Designed to enhance production yields of recombinant human antibodies and proteins on mammalian cell lines

Virosomes

A vehicle enabling the use of virus antigens in the making of vaccines